1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Blood Transfusion Diagnostics Market
4. Market Overview
4.1. Introduction
4.1.1. Product Definition
4.1.2. Industry Evolution/Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Blood Transfusion Diagnostics Market Analysis and Forecast, 2017–2031
5. Key Insights
5.1. Pipeline Analysis
5.2. Key Product/Brand Analysis
5.3. Key Mergers & Acquisitions
5.4. COVID-19 Pandemic Impact on Industry
6. Global Blood Transfusion Diagnostics Market Analysis and Forecast, by Product Type
6.1. Introduction & Definition
6.2. Key Findings/Developments
6.3. Market Value Forecast, by Product Type, 2017–2031
6.3.1. Instruments
6.3.2. Kits & Reagents
6.4. Market Attractiveness Analysis, by Product Type
7. Global Blood Transfusion Diagnostics Market Analysis and Forecast, by Application
7.1. Introduction & Definition
7.2. Key Findings/Developments
7.3. Market Value Forecast, by Application, 2017–2031
7.3.1. Blood Grouping
7.3.2. Disease Screening
7.3.2.1. Molecular Disease Screening
7.3.2.2. Serological Disease Screening
7.4. Market Attractiveness Analysis, by Application
8. Global Blood Transfusion Diagnostics Market Analysis and Forecast, by End-user
8.1. Introduction & Definition
8.2. Key Findings/Developments
8.3. Market Value Forecast, by End-user, 2017–2031
8.3.1. Hospitals
8.3.2. Diagnostics Laboratories
8.3.3. Blood Banks
8.3.4. Plasma Fractionation Companies
8.3.5. Others
8.4. Market Attractiveness Analysis, by Application
9. Global Blood Transfusion Diagnostics Market Analysis and Forecast, by Region
9.1. Key Findings
9.2. Market Value Forecast, by Region, 2017–2031
9.2.1. North America
9.2.2. Europe
9.2.3. Asia Pacific
9.2.4. Latin America
9.2.5. Middle East & Africa
9.3. Market Attractiveness Analysis, by Region
10. North America Blood Transfusion Diagnostics Market Analysis and Forecast
10.1. Introduction
10.2. Key Findings
10.3. Market Value Forecast, by Product Type, 2017–2031
10.3.1. Instruments
10.3.2. Kits & Reagents
10.4. Market Value Forecast, by Application, 2017–2031
10.4.1. Blood Grouping
10.4.2. Disease Screening
10.4.2.1. Molecular Disease Screening
10.4.2.2. Serological Disease Screening
10.5. Market Value Forecast, by End-user, 2017–2031
10.5.1. Hospitals
10.5.2. Diagnostics Laboratories
10.5.3. Blood Banks
10.5.4. Plasma Fractionation Companies
10.5.5. Others
10.6. Market Value Forecast, by Country, 2017–2031
10.6.1. U.S.
10.6.2. Canada
10.7. Market Attractiveness Analysis
10.7.1. By Product Type
10.7.2. By Application
10.7.3. By End-user
10.7.4. By Country
11. Europe Blood Transfusion Diagnostics Market Analysis and Forecast
11.1. Introduction
11.2. Key Findings
11.3. Market Value Forecast, by Product Type, 2017–2031
11.3.1. Instruments
11.3.2. Kits & Reagents
11.4. Market Value Forecast, by Application, 2017–2031
11.4.1. Blood Grouping
11.4.2. Disease Screening
11.4.2.1. Molecular Disease Screening
11.4.2.2. Serological Disease Screening
11.5. Market Value Forecast, by End-user, 2017–2031
11.5.1. Hospitals
11.5.2. Diagnostics Laboratories
11.5.3. Blood Banks
11.5.4. Plasma Fractionation Companies
11.5.5. Others
11.6. Market Value Forecast, by Country/Sub-region, 2017–2031
11.6.1. Germany
11.6.2. U.K.
11.6.3. France
11.6.4. Italy
11.6.5. Spain
11.6.6. Rest of Europe
11.7. Market Attractiveness Analysis
11.7.1. By Product Type
11.7.2. By Application
11.7.3. By End-user
11.7.4. By Country/Sub-region
12. Asia Pacific Blood Transfusion Diagnostics Market Analysis and Forecast
12.1. Introduction
12.2. Key Findings
12.3. Market Value Forecast, by Product Type, 2017–2031
12.3.1. Instruments
12.3.2. Kits & Reagents
12.4. Market Value Forecast, by Application, 2017–2031
12.4.1. Blood Grouping
12.4.2. Disease Screening
12.4.2.1. Molecular Disease Screening
12.4.2.2. Serological Disease Screening
12.5. Market Value Forecast, by End-user, 2017–2031
12.5.1. Hospitals
12.5.2. Diagnostics Laboratories
12.5.3. Blood Banks
12.5.4. Plasma Fractionation Companies
12.5.5. Others
12.6. Market Value Forecast, by Country/Sub-region, 2017–2031
12.6.1. China
12.6.2. Japan
12.6.3. India
12.6.4. Australia & New Zealand
12.6.5. Rest of Asia Pacific
12.7. Market Attractiveness Analysis
12.7.1. By Product Type
12.7.2. By Application
12.7.3. By End-user
12.7.4. By Country/Sub-region
13. Latin America Blood Transfusion Diagnostics Market Analysis and Forecast
13.1. Introduction
13.2. Key Findings
13.3. Market Value Forecast, by Product Type, 2017–2031
13.3.1. Instruments
13.3.2. Kits & Reagents
13.4. Market Value Forecast, by Application, 2017–2031
13.4.1. Blood Grouping
13.4.2. Disease Screening
13.4.2.1. Molecular Disease Screening
13.4.2.2. Serological Disease Screening
13.5. Market Value Forecast, by End-user, 2017–2031
13.5.1. Hospitals
13.5.2. Diagnostics Laboratories
13.5.3. Blood Banks
13.5.4. Plasma Fractionation Companies
13.5.5. Others
13.6. Market Value Forecast, by Country/Sub-region, 2017–2031
13.6.1. Brazil
13.6.2. Mexico
13.6.3. Rest of Latin America
13.7. Market Attractiveness Analysis
13.7.1. By Product Type
13.7.2. By Application
13.7.3. By End-user
13.7.4. By Country/Sub-region
14. Middle East & Africa Blood Transfusion Diagnostics Market Analysis and Forecast
14.1. Introduction
14.2. Key Findings
14.3. Market Value Forecast, by Product Type, 2017–2031
14.3.1. Instruments
14.3.2. Kits & Reagents
14.4. Market Value Forecast, by Application, 2017–2031
14.4.1. Blood Grouping
14.4.2. Disease Screening
14.4.2.1. Molecular Disease Screening
14.4.2.2. Serological Disease Screening
14.5. Market Value Forecast, by End-user, 2017–2031
14.5.1. Hospitals
14.5.2. Diagnostics Laboratories
14.5.3. Blood Banks
14.5.4. Plasma Fractionation Companies
14.5.5. Others
14.6. Market Value Forecast, by Country/Sub-region, 2017–2031
14.6.1. GCC Countries
14.6.2. South Africa
14.6.3. Rest of Middle East & Africa
14.7. Market Attractiveness Analysis
14.7.1. By Product Type
14.7.2. By Application
14.7.3. By End-user
14.7.4. By Country/Sub-region
15. Competition Landscape
15.1. Market Player – Competitive Matrix (by Tier and Size of Companies)
15.2. Market Share Analysis, by Company (2022)
15.3. Company Profiles
15.3.1. Grifols, S.A.
15.3.1.1. Company Overview
15.3.1.2. Product Portfolio
15.3.1.3. SWOT Analysis
15.3.1.4. Financial Overview
15.3.1.5. Strategic Overview
15.3.2. Werfen
15.3.2.1. Company Overview
15.3.2.2. Product Portfolio
15.3.2.3. SWOT Analysis
15.3.2.4. Financial Overview
15.3.2.5. Strategic Overview
15.3.3. Ortho Clinical Diagnostics
15.3.3.1. Company Overview
15.3.3.2. Product Portfolio
15.3.3.3. SWOT Analysis
15.3.3.4. Financial Overview
15.3.3.5. Strategic Overview
15.3.4. Abbott
15.3.4.1. Company Overview
15.3.4.2. Product Portfolio
15.3.4.3. SWOT Analysis
15.3.4.4. Financial Overview
15.3.4.5. Strategic Overview
15.3.5. Bio-Rad Laboratories, Inc.
15.3.5.1. Company Overview
15.3.5.2. Product Portfolio
15.3.5.3. SWOT Analysis
15.3.5.4. Financial Overview
15.3.5.5. Strategic Overview
15.3.6. F. Hoffmann-La Roche AG
15.3.6.1. Company Overview
15.3.6.2. Product Portfolio
15.3.6.3. SWOT Analysis
15.3.6.4. Financial Overview
15.3.6.5. Strategic Overview
15.3.7. Alive Dx
15.3.7.1. Company Overview
15.3.7.2. Product Portfolio
15.3.7.3. SWOT Analysis
15.3.7.4. Financial Overview
15.3.7.5. Strategic Overview
15.3.8. BAG Health Care GmbH
15.3.8.1. Company Overview
15.3.8.2. Product Portfolio
15.3.8.3. SWOT Analysis
15.3.8.4. Financial Overview
15.3.8.5. Strategic Overview
15.3.9. DiaSorin S.p.A.
15.3.9.1. Company Overview
15.3.9.2. Product Portfolio
15.3.9.3. SWOT Analysis
15.3.9.4. Financial Overview
15.3.9.5. Strategic Overview
15.3.10. Hologic, Inc.
15.3.10.1. Company Overview
15.3.10.2. Product Portfolio
15.3.10.3. SWOT Analysis
15.3.10.4. Financial Overview
15.3.10.5. Strategic Overview
*** 免責事項 ***
https://www.globalresearch.co.jp/disclaimer/